Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Parpvax: Niraparib + Ipilimumab or Nivolumab in Advanced Pancreatic Cancer
NCT03404960Phase 2Completed
- Sponsor
- University of Pennsylvania
- Start
- Jan 2018
- Primary completion
- Apr 2022
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of niraparib, nivolumab, ipilimumab in pancreatic adenocarcinoma (PDAC), sponsored by University of Pennsylvania. Started Jan 2018; status: completed.
02
Drugs
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03404960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03404960.